Daraxonrasib Signals a Potential Turning Point in Pancreatic Cancer

An experimental RAS-targeted therapy more than doubled median overall survival against standard chemotherapy in a closely watched pancreatic-cancer study. Broader confirmation and regulatory review remain necessary.